Ian E. Krop MD, PhD

Ian E. Krop, MD, PhD, is the Associate Cancer Center Director for Clinical Research and Chief Clinical Research Officer at Yale Cancer Center. He also directs the Cancer Center’s Clinical Trial Office and is Professor of Medicine at Yale School of Medicine in New Haven, Connecticut. Additionally, Dr. Krop serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).

Dr. Krop received his medical degree and PhD degree from Johns Hopkins University in Baltimore, Maryland. He subsequently completed his residency in internal medicine at Johns Hopkins Hospital followed by a fellowship in hematology and medical oncology at Dana-Farber Cancer Institute in Boston, Massachusetts.

Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2-positive breast cancer. He has been a leader in the development of antibody-drug conjugates in breast cancer including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan.